NeuroPace forecasts 2026 revenue USD 99 million-101 million

NeuroPace

NeuroPace

NPCE

0.00
  • Neuropace forecast 2026 revenue of USD 99 million to USD 101 million, with RNS revenue growth of 21%-23%.
  • Guidance assumes continued 20%+ RNS growth driven by prescriber expansion, higher utilization, commercial execution.
  • Non-GAAP gross margin expected at 81.5%-82.5% with non-GAAP operating expense of USD 90 million-92 million.
  • Adjusted EBITDA projected at a loss of USD 8.5 million to USD 9.5 million.
  • Outlook follows 2025 revenue of USD 100 million, up 25%, with Q1 2026 non-GAAP revenue of USD 22 million, up 20% year over year.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.